A-966492 |
A dual inhibitor of PARP1 and PARP2 (Kis = 1 and 1.5 nM, respectively); re… |
25 mg |
26378-25 |
More Info
|
A-966492 |
A dual inhibitor of PARP1 and PARP2 (Kis = 1 and 1.5 nM, respectively); re… |
5 mg |
26378-5 |
More Info
|
A-967079 |
A potent, selective, and bioavailable inhibitor of the TRPA1 channel, with… |
10 mg |
15207-10 |
More Info
|
A-967079 |
A potent, selective, and bioavailable inhibitor of the TRPA1 channel, with… |
25 mg |
15207-25 |
More Info
|
A-967079 |
A potent, selective, and bioavailable inhibitor of the TRPA1 channel, with… |
5 mg |
15207-5 |
More Info
|
A-967079 |
A potent, selective, and bioavailable inhibitor of the TRPA1 channel, with… |
50 mg |
15207-50 |
More Info
|
A-971432 |
An S1P5 agonist that is selective for S1P5 over S1P1 and S1P3 (IC50s = 0.0… |
1 mg |
25326-1 |
More Info
|
A-971432 |
An S1P5 agonist that is selective for S1P5 over S1P1 and S1P3 (IC50s = 0.0… |
10 mg |
25326-10 |
More Info
|
A-971432 |
An S1P5 agonist that is selective for S1P5 over S1P1 and S1P3 (IC50s = 0.0… |
25 mg |
25326-25 |
More Info
|
A-971432 |
An S1P5 agonist that is selective for S1P5 over S1P1 and S1P3 (IC50s = 0.0… |
5 mg |
25326-5 |
More Info
|
A1-28 |
An ionizable cationic lipid; has been used in the generation of LNPs for t… |
1 mg |
39590-1 |
More Info
|
A1-28 |
An ionizable cationic lipid; has been used in the generation of LNPs for t… |
5 mg |
39590-5 |
More Info
|
A1-28 |
An ionizable cationic lipid; has been used in the generation of LNPs for t… |
500 µg |
39590-500 |
More Info
|
1A-116 |
An inhibitor of Rac1 (IC50 = 4 µM); reduces the secretion of CXCL5,… |
10 mg |
40781-10 |
More Info
|
1A-116 |
An inhibitor of Rac1 (IC50 = 4 µM); reduces the secretion of CXCL5,… |
100 mg |
40781-100 |
More Info
|
1A-116 |
An inhibitor of Rac1 (IC50 = 4 µM); reduces the secretion of CXCL5,… |
50 mg |
40781-50 |
More Info
|
A17 |
A bile acid derivative; reduces oleic acid-induced triglyceride accumulati… |
100 mg |
39686-100 |
More Info
|
A17 |
A bile acid derivative; reduces oleic acid-induced triglyceride accumulati… |
25 mg |
39686-25 |
More Info
|
A17 |
A bile acid derivative; reduces oleic acid-induced triglyceride accumulati… |
250 mg |
39686-250 |
More Info
|
A17 |
A bile acid derivative; reduces oleic acid-induced triglyceride accumulati… |
50 mg |
39686-50 |
More Info
|
A-39183A |
An antibiotic; produced by aerobic fermentation of Streptomyces NRRL 12049… |
1 mg |
23239-1 |
More Info
|
A-39183A |
An antibiotic; produced by aerobic fermentation of Streptomyces NRRL 12049… |
5 mg |
23239-5 |
More Info
|
A-54556A |
An ADEP antibiotic; active against B. subtilis, S. pyogenes, and E. faecal… |
1 mg |
15305-1 |
More Info
|
A-54556A |
An ADEP antibiotic; active against B. subtilis, S. pyogenes, and E. faecal… |
5 mg |
15305-5 |
More Info
|
AA147 |
An ER proteostasis regulator; activates an ATF6-dependent ER stress respon… |
10 mg |
27143-10 |
More Info
|
AA147 |
An ER proteostasis regulator; activates an ATF6-dependent ER stress respon… |
100 mg |
27143-100 |
More Info
|
AA147 |
An ER proteostasis regulator; activates an ATF6-dependent ER stress respon… |
5 mg |
27143-5 |
More Info
|
AA147 |
An ER proteostasis regulator; activates an ATF6-dependent ER stress respon… |
50 mg |
27143-50 |
More Info
|
AA26-8 |
A pan-serine hydrolase inhibitor; inhibits APEH, PAF-AH2, ABHD11, LYPLA1,… |
10 mg |
36937-10 |
More Info
|
AA26-8 |
A pan-serine hydrolase inhibitor; inhibits APEH, PAF-AH2, ABHD11, LYPLA1,… |
25 mg |
36937-25 |
More Info
|
AA26-8 |
A pan-serine hydrolase inhibitor; inhibits APEH, PAF-AH2, ABHD11, LYPLA1,… |
5 mg |
36937-5 |
More Info
|
AA26-8 |
A pan-serine hydrolase inhibitor; inhibits APEH, PAF-AH2, ABHD11, LYPLA1,… |
50 mg |
36937-50 |
More Info
|
AA-861 |
A 5-LO inhibitor (IC50 = 0.8 µM); >100-fold selective for 5-LO over… |
1 mg |
13263-1 |
More Info
|
AA-861 |
A 5-LO inhibitor (IC50 = 0.8 µM); >100-fold selective for 5-LO over… |
500 µg |
13263-500 |
More Info
|
AA92593 |
An OPN4 receptor antagonist (Ki = 16 nM); inhibits light-induced calcium t… |
10 mg |
35836-10 |
More Info
|
AA92593 |
An OPN4 receptor antagonist (Ki = 16 nM); inhibits light-induced calcium t… |
25 mg |
35836-25 |
More Info
|
AA92593 |
An OPN4 receptor antagonist (Ki = 16 nM); inhibits light-induced calcium t… |
5 mg |
35836-5 |
More Info
|
AA92593 |
An OPN4 receptor antagonist (Ki = 16 nM); inhibits light-induced calcium t… |
50 mg |
35836-50 |
More Info
|
AA43279 |
An Nav1.1 activator (EC50 = 9.5 µM in a patch-clamp assay using HEK2… |
10 mg |
40428-10 |
More Info
|
AA43279 |
An Nav1.1 activator (EC50 = 9.5 µM in a patch-clamp assay using HEK2… |
25 mg |
40428-25 |
More Info
|
AA43279 |
An Nav1.1 activator (EC50 = 9.5 µM in a patch-clamp assay using HEK2… |
5 mg |
40428-5 |
More Info
|
AA43279 |
An Nav1.1 activator (EC50 = 9.5 µM in a patch-clamp assay using HEK2… |
50 mg |
40428-50 |
More Info
|
AAA |
A GPR75 antagonist; increases basal GPR75 protein levels and inhibits 20-H… |
1 mg |
32733-1 |
More Info
|
AAA |
A GPR75 antagonist; increases basal GPR75 protein levels and inhibits 20-H… |
500 µg |
32733-500 |
More Info
|
7-AAD/CFSE Cell-Mediated Cytotoxicity Assay Kit |
Cayman's 7-AAD / CFSE Cell-Mediated Cytotoxicity Assay Kit employs CFSE to… |
1 ea |
600120-1EA |
More Info
|
AA3-DLin |
An ionizable cationic amino lipid (pKa = 5.8); has been used in combinatio… |
10 mg |
37903-10 |
More Info
|
AA3-DLin |
An ionizable cationic amino lipid (pKa = 5.8); has been used in combinatio… |
25 mg |
37903-25 |
More Info
|
AA3-DLin |
An ionizable cationic amino lipid (pKa = 5.8); has been used in combinatio… |
5 mg |
37903-5 |
More Info
|
AAF-CMK (trifluoroacetate salt) |
An irreversible inhibitor of TPPII commonly used at 10-100 µM; does… |
10 mg |
14461-10 |
More Info
|
AAF-CMK (trifluoroacetate salt) |
An irreversible inhibitor of TPPII commonly used at 10-100 µM; does… |
25 mg |
14461-25 |
More Info
|